Identification of prognostic inflammatory factors in colorectal liver metastases

BMC Cancer

Trevor D Hamilton²  Derek Leugner¹  Karen Kopciuk¹  Elijah Dixon²  Francis R Sutherland²  Oliver F Bathe³ 

[1] Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada

[2] Department of Surgery, University of Calgary, Calgary, AB, Canada

[3] Department of Oncology, University of Calgary, 1331-29th St NW, Calgary T2N 4N2, AB, Canada

关键词: Surgery;    Prognostic;    Cytokine;    CRP;    Inflammatory;    Metastases;    Liver;    Cancer;    Colorectal;   

Others  :  1125290
DOI  :  10.1186/1471-2407-14-542

 received in 2013-07-04, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

The modified Glasgow Prognostic Score (mGPS) has been reported to be an important prognostic indicator in a number of tumor types, including colorectal cancer (CRC). The features of the inflammatory state thought to accompany elevated C-reactive protein (CRP), a key feature of mGPS, were characterized in patients with colorectal liver metastases. Additional inflammatory mediators that contribute to prognosis were explored.

Methods

In sera from 69 patients with colorectal liver metastases, a panel of 42 inflammatory mediators were quantified as a function of CRP levels, and as a function of disease-free survival. Multivariate statistical methods were used to determine association of each mediator with elevated CRP and truncated disease-free survival.

Results

Elevated CRP was confirmed to be a strong predictor of survival (HR 4.00, p = 0.001) and recurrence (HR 3.30, p = 0.002). The inflammatory state associated with elevated CRP was comprised of raised IL-1β, IL-6, IL-12 and IL-15. In addition, elevated IL-8 and PDGF-AB/BB and decreased eotaxin and IP-10 were associated with worse disease-free and overall survival.

Conclusions

Elevated CRP is associated with a proinflammatory state. The inflammatory state is an important prognostic indicator in CRC liver metastases. The individual contributions of tumor biology and the host to this inflammatory response will require further investigation.

【 授权许可】

   
2014 Hamilton et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Finlay IG, McArdle CS: Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986, 73:732-735.
• [2]Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S: A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 2009, 9:1-10. BioMed Central Full Text
• [3]Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005, 241:715-724.
• [4]Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S: Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006, 13:668-676.
• [5]Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 1999, 230:309-321.
• [6]Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE: Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999, 189:291-299.
• [7]Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, Kulisch E, Saeger HD: Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 2009, 29:89-102.
• [8]Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P: Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg 2001, 25:638-644.
• [9]Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M: Simplified staging system for predicting the prognosis of patients with resectable liver metastasis. Arch Surg 2007, 142:269-276.
• [10]Nagashima I, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, Okinaga K: A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 2004, 11:79-83.
• [11]Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008, 247:125-135.
• [12]Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ: Prognostic scoring in colorectal cancer liver metastases. Arch Surg 2005, 140:183-189.
• [13]Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T: Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000, 231:59-66.
• [14]McMillan DC, Crozier JEM, Canna K, Angerson WJ, McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007, 22:881-886.
• [15]Forrest LM, McMillan DC, McArdle CS, Anderson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003, 89:1028-1030.
• [16]Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K: Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 2007, 246:1047-1051.
• [17]Roxburgh CSD, Salmond JM, Horgan PG, Oien KA, McMillan DC: Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009, 249:788-793.
• [18]Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Miki K, Kobayashi K, Morita K: Elevated c-reactive protein and hypoalbuminemia measure before resection of colorectal liver metastases predict postoperative survival. Dig Surg 2010, 27:285-290.
• [19]Wong VKH, Malik HZ, Hamady ZZR, Al-Mukhtar A, Gomez D, Prasad KR, Toogood GJ, Lodge JP: C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007, 96:222-225.
• [20]Ishizuka M, Kita J, Shimoda M, Rokkaku K, Kato M, Sawada T, et al.: Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Onc 2009, 100:38-42.
• [21]Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, Lodge JP, Toogood GJ: Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007, 246:806-814.
• [22]McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003, 90:215-219.
• [23]Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248-252.
• [24]Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005, 92:21-23.
• [25]Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS, McMillan DC: Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 2007, 96:891-895.
• [26]Hilmy M, Bartlett JMS, Underwood MA, McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005, 92:625-627.
• [27]Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008, 14:710-714.
• [28]Karakiewicz PI, Hutterer GC, Trinh Q, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. Cancer 2007, 110:1241-1247.
• [29]Friedman J, Hastie T, Tibshirani R: Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010, 33:1-22.
• [30]Simon N, Friedman J, Hastie T, Tibshirani R: Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw 2011, 39:1-13.
• [31]Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 2001, 98:5116-5121.
• [32]Chung YC, Chang YF: Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003, 50:1910-1913.
• [33]Ito H, Miki C: Profile of circulating levels of interleukin-1 receptor antagonist and interleuking-6 in colorectal cancer patients. Scand J Gastroenterol 1999, 11:1139-1143.
• [34]Knupfer H, Preiss R: Serum interleukin-6 levels in colorectal cancer patients – a summary of published results. Int J Colorectal Dis 2010, 25:135-140.
• [35]Guthrie GJK, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC: Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer 2013, 109:131-137.
• [36]Li A, Varney ML, Singh RK: Expression of interleukin 8 and its receptors in humon colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001, 7:3298-3304.
• [37]Waugh DJJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
• [38]Peterson JE, Zurakowski D, Italiano JE, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15:265-273.
• [39]Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, Sherlock DJ, Hawkins RE, Gilham DE: Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 2007, 13:5719-5728.
• [40]Wagsater D, Lofgren S, Hugander A, Dienus O, Dimberg J: Analysis of single nucleotide polymorphism in the promoter protein expression of the chemokine Eotaxin-1 in colorectal cancer patients. World J Surg Oncol 2007, 5:84. BioMed Central Full Text
• [41]Sgadari C, Angiolillo A, Cherney B, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci 1996, 93:13791-13796.
• [42]Reckamp K, Figlin R, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM: Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 2007, 30:417-424.
• [43]Jiang Z, Xu Y, Cai S: CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep 2010, 37:3029-3036.
• [44]Wang D, Luo H, Qiu M, Wang Z, Zhang D, Wang F, Li YH, Xu RH: Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 2012, 29:3092-3100.
• [45]Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H, Tajiri H: Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer 2012, 107:988-993.
• [46]Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
• [47]Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal liver metastases? Ann Surg 2004, 240:1052-1061.
• [48]Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012, 10:51. BioMed Central Full Text